Abstract: A modified ?-gliadin (polypeptide) free of toxicity or with less toxicity as compared to the predominant wild-type form, ideal for the preparation of food intended for individuals suffering from celiac disease or individuals prone to developing the disease. The invention further relates to DNA sequences encoding the modified ?-gliadins, organisms capable of producing such modified ?-gliadins and products including such modified ?-gliadins.

Abstract: Disclosed herein are methods inducing an antigen specific immune response, methods of interrupting malaria transmission, and methods of treating and/or preventing malaria. Disclosed herein are mRNA molecules, viral vectors, mRNA vaccines, and pharmaceutical formulations for use in the disclosed methods.

Abstract: Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.

Abstract: The present disclosure provides methods for treating or ameliorating a myelin associated disease or a mitochondria associated disease that comprising administering to a subject in need thereof a frataxin replacement therapeutic compound, e.g., a fusion protein comprising frataxin.

Abstract: The present invention provides a hypoxia-triggered artificial transcription factor (HATF), and further provides a hypoxia-triggered transcription control system. The transcription control system comprises a nucleic acid sequence encoding the HATF, and a recognition element (RE). The hypoxia-triggered transcription control system comprises two sets of transcription control units linked upstream and downstream, wherein the upstream transcription control unit comprises a hypoxia-triggered transcription reaction element for controlling the HATF and a nucleic acid sequence encoding the HATF, and the downstream transcription control unit comprises an RE and a gene of interest. Co-regulation by the artificial transcription factor HATF and the recognition element RE can increase the expression of the gene of interest by a factor of one hundred.

Abstract: The invention provides compositions and methods for treating tuberous sclerosis complex (TSC). In particular, provided are condensed tuberins (cTuberins), cTuberin nucleic acids, and recombinant adeno-associated viruses (rAAVs) carrying a cTuberin nucleic acid for treating a patient with TSC.

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.

Abstract: GDF15 fusion proteins and uses thereof, the fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.

Abstract: The present invention relates to fusion proteins comprising a ligand binding domain, a protease cleavage site, and a ligand moiety. The fusion proteins of the invention comprise a ligand binding domain, a ligand moiety, and a protease cleavage site that, when activated by cleavage by a protease, restores biological activity of the ligand. The invention also relates to methods of producing the fusion proteins, their uses and pharmaceutical compositions comprising said fusion proteins. The present invention also relates to a method of reducing the association between heavy chain variable domain (VH) and light chain variable domain (VL) within the ligand binding domain that promotes dissociation of one from the other. The present disclosure provides fusion proteins in which the ligand is fused to the C-terminus of the constant region, or the N-terminus of the ligand binding domain.

Abstract: The invention discloses a fusion protein and its preparation method for intermediate polypeptide of Semaglutide. The invention belongs to the technical field of genetic engineering and polypeptide preparation. The fusion protein comprises a fusion peptide, a protease cleavage site and a target main molecular sequence. By optimizing the fusion peptide sequence, changing the isoelectric point and hydrophilicity of the protein, the highest expression of the fusion protein is effectively increased to 13.1 g/L. Meanwhile, the properties of fusion protein are also improved, which is conducive to the development of subsequent extraction, enzyme digestion and purification processes. The yield of intermediate polypeptide after enzyme digestion is 3.62 g/L. The production cost of Semaglutide intermediate polypeptide Arg34GLP-1(9-37) is reduced from the source, which is conducive to industrial scale-up and suitable for industrial production.

Abstract: The subject matter of this invention is directed towards insulin analogs that are stable and glucose-responsive. An insulin analog can be a single chain insulin (SCI). The binding affinity of insulin to the insulin receptor can be controlled by the glucose-bound conformation of insulin. The invention further discloses methods for the recombinant expression, purification, and refolding of an insulin analog.

Abstract: The present disclosure provides compositions and methods for decreasing permissiveness to infection by PRRSV. The methods involve inserting peptides or oligopeptides into the CD163 SRCR domain 5 to disrupt the protein structure and thereby prevent PRRSV infection. The deletion of the exon 13 region of PSTII eliminates infection. The replacement of cysteine residues with alanines in SRCR5 as a means to disrupt disulfide bond formation. The final method is the deletion of, or amino acid substitution within the SRCR4-5 interdomain region.

Abstract: The present invention relates to chimeric antigen receptors (CAR) comprising of two or more binding domains that binds CD19, CD20 or CD22 and at least two or more intracellular co-stimulatory signaling domains selected from the group consisting of CD28, 41BB, OX40 and ICOS. The CAR may further comprise of a hinge or spacer region, a transmembrane region, an intracellular signaling domain and a linker region. The CAR and compositions thereof of the invention is used in the treatment of B-cell malignancies.

Abstract: The present invention is directed to the use of anion exchange chromatography to produce a CTLA4-Ig fusion protein with improve glycan.

Abstract: Modular synthetic receptors are provided. The synthetic receptors may include an extracellular domain capable of binding to one or more ligand molecules and may be released from the synthetic receptor after binding, a transmembrane domain derived from the Notch receptor, and an intracellular domain which may have one or more functional activities when released from the synthetic receptor. A method of use for the synthetic receptors is also provided, wherein upon binding of the extracellular domain to a specific ligand, the synthetic receptor undergoes proteolytic cleavage to release either or both the extracellular and intracellular domains. The extracellular binding domain, if released, may continue to bind to its cognate ligand and may carry one or more additional functional activities and the intracellular domain, if released, may stimulate or inhibit one or more intracellular activities.

Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.

Abstract: An activator for preserving and regenerating muscle structure and function activates the thyroid-stimulating hormone receptor (TSHR) signaling pathway in muscle stem cells (satellite cells), thereby blocking senescence. A medical product includes a plurality of activators, such as a genetic activator, and an adenoviral vector comprising a thyroid-stimulating hormone receptor (TSHR) protein sequence of SEQ ID NO: 1, or a TSHR nucleotide sequence of SEQ ID NO: 2.

Abstract: Polynucleotides are made encoding amino acid sequences that are at least 60% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9. The polypeptide is a replicable polypeptide encoding a collagen-like protein and the amino acid sequence includes a deletion of at least 38 amino acids at the N-terminus of the amino acid sequence of SEQ ID NO:1 and respective polypeptides. A fermentative process for secreting bacterial collagen-like proteins in a host is developed.

Abstract: The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.

Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

Abstract: Methods for treatment or prevention of medication overuse headache are provided. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Disclosed are an intracellular antibody (intrabody) and a preparation method and a use thereof. The intrabody includes a fragment of the variable region of the heavy chain (VH) of a monoclonal antibody that recognizes mutant huntingtin (mHTT) and a signal sequence of lysosome-associated membrane protein I (LAMP1). The VH fragment includes an amino acid sequence as shown in any one of SEQ. ID NO. 1-3. The intrabody described in this application possesses a bidirectional recognition function, enabling it to bind to and recognize mHTTs as well as specifically recognize lysosomes, thereby realizing the targeted degradation of mutant proteins and improving the degradation efficiency of the mutant proteins.

Abstract: The present disclosure relates to methods, uses, and compositions for the treatment of Sickle cell disease (SCD), beta thalassemia (BT), or sickle cell BT. More specifically, the disclosure concerns the treatment of patients having SCD. BT, or sickle cell BT using a complement C5 inhibitor, such as an anti-C5 antibody or fragment thereof, a nucleic acid molecule, a peptide, a small molecule, or an aptamer.

Abstract: The present invention relates to methods, uses, and compositions for the treatment of Sickle cell disease (SCD), beta thalassemia (BT), sickle cell BT. More specifically, the invention concerns the treatment of patients having SCD, BT, or sickle cell BT using a complement pathway component (e.g., Factor P (properdin)) inhibitor, such as an antibody or fragment thereof, a nucleic acid molecule, a peptide, a small molecule, or an aptamer, among others.

Abstract: This invention disclosure describes novel polypeptide antagonists capable of neutralizing multiple members of TGF-? family in a selective manner. Specifically, the multispecific polypeptide antagonists disclosed herein comprise at least one Activin-binding domain and at least one TGF-?-binding domain and therefore, are capable of neutralizing TGF-? and Activin as well as Activin-related ligands in parallel. Moreover, this invention disclosure also discloses bifunctional multispecific polypeptide antagonists designed to inhibit Activin, TGF-? and T-Cell immune checkpoint (i.e., PD1, PDL1 or CTLA4) in a simultaneous manner. Specifically, the bifunctional multispecific antagonists disclosed herein comprise at least one Activin-binding domain, at least one TGF-?-binding domain and at least one PD1-, PDL1- or CTLA4-binding domain.

Abstract: The present invention provides novel IGFR-L1 antibodies for targeting extracellular domain of non-denatured IGFR-L1 protein. Said antibodies are envisaged for use as a medicament, and in particular for treatment of diabetes and related disorders and cancer.

Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

Abstract: A bispecific fusion polypolypeptide that binds to vascular endothelial growth factor (VEGF) A and VEGFC is provided, comprising a first domain that specifically recognizes VEGFA and a second domain that specifically recognizes VEGFC. Also provided is a method for treating or preventing diseases related to VEGFA or VEGFC by the described bispecific fusion polypeptide.

Abstract: A composition including a neutralizing antibody to CXCL12 for treatment of hair loss is provided. The neutralizing antibody to CXCL12 inhibits CXCL12 to exhibit an effect of promoting hair growth, and thus can be advantageously used for preventing or treating hair loss.

Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.

Abstract: The present invention relates to the treatment of cancer of the intestine. The invention extends to inhibitors of the IL-25:IL-25R signalling pathway, which specifically bind to IL-25 or to IL-25R, for use in methods of treating, preventing, or amelio-rating cancer of the intestine.

Abstract: Provided herein are liquid compositions comprising a high concentration of a monoclonal antibody, e.g., greater than about 100 mg/mL, which demonstrate storage-stability and reduced viscosity. In exemplary embodiments, the liquid composition comprises about less than about 400 mM arginine glutamate, and, in alternative exemplary embodiments, the liquid composition comprises proline and a buffer.

Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.

Abstract: The present invention provides methods and compositions for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

Abstract: The present invention relates to an antibody specifically binding to CD79b and a bispecific antibody specifically binding to CD79b and CD3, nucleic acids encoding the anti-CD79b antibody and the anti-CD79b×CD3 bispecific antibody, vectors comprising the nucleic acids, host cells comprising the nucleic acids or the vectors, and pharmaceutical compositions comprising the antibodies or antigen-binding fragments thereof.

Abstract: This disclosure relates generally to proteins target tumor cell killing comprising: a polypeptide or complex of two or more polypeptides that specifically binds ROR1, and a polypeptide or complex of two or more polypeptides that specifically binds CD3. In some embodiments, the present application provides antibodies that specifically bind ROR1. In some embodiments the application also provides therapeutic methods for using such proteins in the treatment of a cancer.

Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.

Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

Abstract: The present disclosure relates to a bispecific antibody capable of specifically binding PVRIG and TIGIT, which can modulate the function of immune cells and can be used as a drug to treat diseases related to immune abnormalities, such as tumors.

Abstract: This document provides methods and materials for assessing and/or treating mammals (e.g., humans) having mesothelioma (e.g., mesothelioma with a high junction burden). For example, methods and materials that can be used to determine whether or not a mammal having mesothelioma is likely to respond to a particular cancer treatment (e.g., immunotherapy with one or more immune checkpoint inhibitors) are provided. Methods and materials for treating a mammal (e.g., a human) having mesothelioma (e.g., mesothelioma with a high junction burden) where the treatment is selected based, at least in part, on whether or not the mammal is likely to respond to a particular cancer treatment (e.g., immunotherapy with one or more immune checkpoint inhibitors) also are provided.

Abstract: The present disclosure describes a bispecific antibody targeting human programmed death-1 (PD-1) and human transforming growth factor ? receptor 2 (TGF?R2) for use in the treatment of disorder such as non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ovarian cancer, breast cancer, bladder cancer, renal cell carcinoma, melanoma, gastric adenocarcinoma, esophageal cancer, gastroesophageal adenocarcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma, and colorectal cancer (CRC).

Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: Provided is a pharmaceutical composition for treating small cell lung cancer, which comprises an anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and a chemotherapeutic drug. Further provided is the use of the pharmaceutical composition or a kit containing the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof and the chemotherapeutic drug in the preparation of a drug for treating small cell lung cancer. Further provided is a method for treating small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and the chemotherapeutic drug.

Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: A B7-H3 antibody and a use thereof are provided. The heavy chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 6-8, and the light chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 14-16. The B7-H3 antibody can bind to a B7-H3 antigen and/or cells expressing the B7-H3 antigen. A B7-H3×CD3 bispecific antibody is constructed by using the B7-H3 antibody.

Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.

Abstract: The present invention relates to a CD16 antibody and the use thereof. Specifically, disclosed are an antibody or an antigen-binding fragment specifically binding CD16, and an encoding nucleic acid, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof for treating diseases, such as the use thereof in the treatment of tumors. The CD16 antibody holds great significance for the development of a CD16 antibody therapeutic drug and a CD16 detection reagent.

Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.